IO Biotech announced that the University of California Davis Comprehensive Cancer Center has dosed the first patient in its investigator-initiated trial which aims to evaluate IO102-IO103, the company's investigational immune-modulating cancer vaccine, in combination with pembrolizumab in patients with BCG-unresponsive or intolerant, non-muscle invasive bladder cancer (NMIBC). This is one of five investigator-initiated trials IO Biotech is supporting to evaluate IO102-IO103 in combination with different checkpoint inhibitor-based regimens across a variety of cancer types.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 USD | +3.36% | +5.48% | -18.09% |
26/04 | IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors | CI |
15/04 | IO Biotech Announces Marjan Shamsaei as Senior Vice President | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.09% | 101M | |
+21.74% | 46.4B | |
-0.97% | 41.75B | |
+49.62% | 41.37B | |
-3.52% | 29.71B | |
+11.12% | 26.01B | |
-19.37% | 19.52B | |
+31.18% | 12.43B | |
-0.04% | 12.13B | |
+0.39% | 12.18B |
- Stock Market
- Equities
- IOBT Stock
- News IO Biotech, Inc.
- IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer Center